Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Exclusion Criteria

• •1. Life expectancy \<1 year irrespective of valvular heart disease
• •2. Kidney disease with a creatinine clearance ≤30 ml/min
• •3. Known severe liver disease
• •4. Known neuromuscular disease
• •5. Clinically significant anaemia with haemoglobin \<80g/L
• •6. Known inflammatory bowel disease or chronic diarrhea
• •7. Known ongoing bacterial infection
• •8. Known galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
• •9. Current treatment with colchicine, steroids or biologicals for any indication
• •10. Concomitant intake of Cyclosporine, Amiodarone, Clarithromycin, Erythromycin, Omeprazole, Verapamil or other strong inhibitors of CYP3A4 or P-Glycoprotein
• •11. Concomitant intake of Carbamazepin, Phenobarbital, Phenytoin, Rifampicin or other strong inductors of CYP3A4 and P-Glycoprotein
• •12. Permanent pacemaker or implantable cardioverter defibrillator
• •13. History of atrial fibrillation
• •14. Absence of sinus rhythm on hospital admission
• •15. Planned non-cardiac surgery within 30 days
• •16. Known intolerance to colchicine
• •17. Inability to provide written informed consent
• •18. Known or suspected non-compliance, drug or alcohol abuse
• •19. Participation in another clinical trial with an active intervention
• •20. Any other planned cardiac intervention performed in the 7 days before TAVI, concomitantly with TAVI or in the 30 days after TAVI except for percutaneous coronary interventions.